Table 4 Assessment of complications in office and self-injection programs after 1 year

From: Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction

Complications Office injection (N=39) Self-injection (N=74) P-value*
Pain    >0.05
 Yes 2 (5.1%) 5 (6.8%)  
 No 37 (94.9%) 69 (93.2%)  
Priapism (longer than 6 h) 2 (5.1%) 4 (5.4%) >0.05
  37 (94.9%) 70 (94.6%)  
Nodules, indurations, fibrosis    <0.05
 Yes 1 (2.6%) 4 (5.4%)  
 No 38 (97.4%) 70 (94.6%)  
  1. *χ2; Significance level at P<0.05; percentages are calculated for a total of 39 for patients on office injection and a total of 74 for patients on self-injection programs after 1 year.